

Quarterly Statement 2025.

January – September 2025

Quarterly Statement

January – September 2025

Financial Highlights

- Group revenue at € 1,217.8 million (2024: € 1,164.5 million) with core revenue contributing € 1,157.7 million (2024: € 1,019.3 million) corresponding to a core growth of 13.6% (thereof 11.5% organic)
- Underlying EBITDA at € 289.6 million (2024: € 227.5 million) with margin improvement by 4.2%p to 23.8% (2024: 19.5%)
- Underlying core EBITDA at € 281.1 million, margin reaches 24.3% (2024: € 217.1 million and 21.3%)
- Adjusted net income at € 118.7 million (2024: € 65.5 million)
- Free cash flow of € 172.8 million (2024: € 111.5 million)
- Management specifies guidance for Financial Year 2025: Core revenue growth in the upper half of 10.0% - 13.0% and organic core revenue growth in the upper half of 9.0% - 12.0%; underlying core EBITDA margin is confirmed at 25.0% - 26.0%
- Promissory notes of € 228.0 million with maturities between 2028 and 2030 issued in September 2025, used to settle existing promissory notes, which will become due in 2026
- Increase in Ottobock SE & Co. KGaA's subscribed capital by € 57.0 million through conversion of capital reserves in preparation for the IPO

Significant Developments

- Product launches in strategic product categories segments Prosthetics, Neuro-Orthotics and Exoskeletons
- Reimbursement approval of C-Brace in France
- Advancement of technological developments through the acquisitions of Romedis GmbH and Ortho Access SAS as well as investments in Bionic Skins, Musclematrix LLC, Phantom Neuro and Onward Medical
- Expansion of the existing Patient Care network with the acquisitions of Matton Orthopedie NV (Belgium) and Northern Prosthetics Pty Ltd (Australia)
- Ottobock supported the 12th World Para Athletics Championships at Jawaharlal Nehru Stadium (India) as the official technical service partner with 58-strong team on site

Key Performance Indicators

million €	Q3		9M	
	2025	2024	2025	2024
Revenue	417.2	401.7	1,217.8	1,164.5
Revenue growth	3.9%	11.2%	4.6%	7.8%
Core revenue	397.5	353.0	1,157.7	1,019.3
Organic core growth	12.7%	10.8%	11.5%	9.2%
Gross profit	221.7	210.2	645.4	584.8
Gross margin	53.1%	52.3%	53.0%	50.2%
Underlying EBITDA	109.3	89.3	289.6	227.5
Underlying EBITDA margin	26.2%	22.2%	23.8%	19.5%
Underlying core EBITDA	105.8	85.3	281.1	217.1
Underlying core EBITDA margin	26.6%	24.2%	24.3%	21.3%
EBITDA	86.8	85.6	250.4	210.9
EBITDA margin	20.8%	21.3%	20.6%	18.1%
EBIT	51.7	51.6	117.9	98.7
EBIT margin	12.4%	12.8%	9.7%	8.5%
Adjusted net income	50.0	33.9	118.7	65.5
Adjusted net income margin	12.0%	8.4%	9.7%	5.6%
Free cash flow	79.6	75.4	172.8	111.5
Net leverage	2.8	3.7	2.8	3.7
Employees (average FTE)	9,336	9,287	9,256	9,083
Earnings per share*	€ 0.41	€ 0.39	€ 0.87	€ 0.42

* The number of ordinary shares outstanding increased as a result of the capital increases in August and October 2025. The calculation of basic earnings per share for all periods presented is based on the new number of shares.

Business Development

Revenue

Revenue increased by € 53.3 million to € 1,217.8 million in the nine-month period which ended September 30, 2025 (2024: € 1,164.5 million). The acquisitions of Sahva in 2024 as well as Matton, Northern Prosthetics and Ortho Access in 2025 contributed revenue of € 35.7 million, while the divestment of Cascade in September 2024 and the closure of Active Life in December 2024 resulted in a decrease in revenue of € 80.5 million.

Core revenue – representing the proforma revenue without divested or to be divested businesses – has reached € 1,157.7 million (2024: € 1,019.3 million) representing a core growth rate of 13.6% (thereof 11.5% organic).

Revenue by segment

REVENUE BY SEGMENT

	Q3		9M	
million €	2025	2024	2025	2024
EMEA	297.4	266.5	867.3	772.7
Americas	91.7	107.5	266.4	316.3
APAC	28.1	27.6	84.1	75.5
Revenue	417.2	401.7	1,217.8	1,164.5

Within EMEA, revenue increased by € 94.6 million, or 12.2%, to € 867.3 million in the reporting period. This increase was driven by the ramp-up of newly launched products such as the Genium X4 and the expansion of the Taleo family, impacts from spike events and acquisitions of Sahva, Matton and Ortho Access.

Revenue in the Americas amounted to € 266.4 million in 9M 2025, reflecting a decline of €49.9 million or 15.8% compared to the same period in the previous year (2024: € 316.3 million). This decrease was primarily driven by the divestment of Cascade in September 2024 and the closure of Active Life in December 2024. Products & components (B2B) revenue increased, benefitting from the launch of the Genium X4 and the reimbursement inclusion of the Kenevo for K2-level amputees, as well other product highlights such as the mechatronic neuro-orthosis C-Brace.

Within APAC, the revenue increased by € 8.6 million, or 11.4%, to € 84.1 million in the respective period. This increase was driven primarily by strong growth in MPK sales, positive development of newly launched products and the acquisition of Northern Prosthetics in Australia.

CORE REVENUE BY SEGMENT

	Q3		9M	
million €	2025	2024	2025	2024
EMEA	284.4	253.4	828.4	731.5
Americas	86.7	74.3	250.9	218.6
APAC	26.4	25.3	78.4	69.1
Core revenue	397.5	353.0	1,157.7	1,019.3

Revenue by product category

In terms of Ottobock's product categories, products & components (B2B) accounted for the largest share of revenue in the first nine months 2025, generating 53.4%, while patient care (B2C) contributed 41.7%.

REVENUE BY PRODUCT CATEGORY

	Q3		9M	
	2025	2024	2025	2024
million €				
Products and components (B2B)	221.6	192.9	650.1	556.9
Patient care (B2C)	176.0	160.1	507.7	462.4
Core revenue	397.5	353.0	1,157.7	1,019.3
Non-core revenue	19.6	48.7	60.0	145.2
Revenue	417.2	401.7	1,217.8	1,164.5

The B2B business amounted to € 650.1 million and increased by € 93.2 million in the reporting period (2024: € 556.9 million), corresponding to an organic growth of 17.1%. This increase was mainly driven by the ramp-up of newly launched products, impacts from spike events and recent reimbursement expansions.

B2C revenue increased by 9.8%, or € 45.3 million, to € 507.7 million within the respective period (2024: € 462.4 million). This increase was driven by an organic growth of 4.7% and inorganic growth of 5.7%, resulting from the acquisitions of Sahva, Matton, Northern Prosthetics and Ortho Access.

Non-core revenue decreased by 58.6% to € 60.0 million in the reporting period (2024: € 145.2 million). The decrease was mainly due to the divestment of Cascade in September 2024 and the closure of Active Life in December 2024.

ORGANIC GROWTH RATES BY SEGMENT AND PRODUCT CATEGORY

Q3 2025	B2B	B2C	Core	Total
EMEA	16.7%	4.9%	10.7%	10.1%
Americas	18.0%	27.6%	20.5%	17.5%
APAC	6.3%	18.7%	9.2%	6.8%
Group	16.1%	8.2%	12.7%	11.5%

9M 2025	B2B	B2C	Core	Total
EMEA	16.6%	3.3%	9.7%	8.9%
Americas	18.2%	10.0%	16.0%	14.7%
APAC	16.2%	17.7%	16.5%	14.5%
Group	17.1%	4.7%	11.5%	10.5%

Gross Profit

Cost of sales amounted to € 572.4 million in the first nine months of 2025, down € 7.3 million compared to the prior-year period (2024: € 579.7 million). In combination with 4.6% revenue growth, this results in an increase in gross profit by € 60.6 million to € 645.4 million. The gross profit margin improved from 50.2% to 53.0%.

Gross margin development was mainly driven by positive product mix effects with strong revenue growth in Ottobock's high-margin B2B product category and the divestment of the low-margin distribution business Cascade. Further factors contributing to the increase are scaling effects due to Ottobock's established production infrastructure, further utilization of the low-cost manufacturing site in Bulgaria and slightly decreased purchasing costs in the manufacturing sites due to procurement initiatives.

Operating Expenses

Selling and distribution expenses rose by € 4.9 million to € 256.6 million in the first nine months of 2025. Regular cost increases, for example due to raises in salary, were partially offset by normalized sales and marketing expenses after the OTWorld Leipzig and the Paralympic Games took place in 2024. Selling and distribution expenses in relation to revenue decreased from 21.6% to 21.1% due scaling effects enabled by Ottobock's established global sales organization.

Expenses for research and development amounted to € 54.4 million and increased by € 1.8 million in the reporting period (2024: € 52.7 million). This rise was driven by continuous investments into the development and improvement of products and services.

Administrative and other expenses as well as other income increased by € 34.6 million from € 181.8 million in the 9M 2024 to € 216.4 million in the 9M 2025. This was primarily due to higher impairments, largely related to the intended divestment of the human mobility business (€ 31.2 million in 2025 vs. € 17.6 million in 2024, mainly including impairments related to the divestment of Cascade), as well as higher costs related to the IPO and revaluation of the Management Participation Program (MPP).

As a result of the developments and effects described above, the operating profit (EBIT) improved by 19.5% to a total of € 117.9 million, which corresponds to an operating profit margin of 9.7% (2024: 8.5%).

Underlying EBITDA

In the first nine months of 2025, the underlying EBITDA reached € 289.6 million, representing an increase of € 62.1 million or 27.3% compared to the prior-year period (2024: € 227.5 million). This performance was driven by double-digit organic revenue growth, improvements in the gross margin and positive scaling effects due to established sales organization and administrative infrastructure. The gross margin expansion resulted primarily from a more favourable product mix, slightly declining purchasing costs in manufacturing, and the strategic divestment of the low-margin distribution business Cascade.

UNDERLYING EBITDA BY SEGMENT

million €	Q3		9M	
	2025	2024	2025	2024
EMEA	77.0	64.3	208.2	173.5
Americas	24.1	18.5	60.3	39.5
APAC	8.3	6.5	21.0	14.5
Underlying EBITDA	109.3	89.3	289.6	227.5

Underlying core EBITDA amounted to € 281.1 million, representing an increase of € 63.9 million or 29.4% compared to the prior-year period (2024: € 217.1 million). The underlying core EBITDA margin improved from 21.3% in 2024 to 24.3% in 2025. The underlying non-core EBITDA amounted to € 8.5 million. This is a decrease by € 1.8 million or 17.6% in the reporting period (2024: € 10.4 million).

UNDERLYING CORE EBITDA BY SEGMENT

million €	Q3		9M	
	2025	2024	2025	2024
EMEA	74.2	61.5	201.9	166.1
Americas	23.5	17.7	59.0	37.5
APAC	8.0	6.1	20.1	13.5
Underlying Core EBITDA	105.9	85.3	281.1	217.1

RECONCILIATION OF PROFIT BEFORE TAX TO THE UNDERLYING CORE EBITDA

	Q3		9M	
million €	2025	2024	2025	2024
Profit before tax	40.3	33.5	86.1	41.6
Financial result	11.4	18.1	31.8	57.1
Operating profit (EBIT)	51.7	51.6	117.9	98.7
Depreciation and amortization	34.1	32.0	101.3	94.7
Impairment	1.0	2.0	31.2	17.6
EBITDA	86.8	85.6	250.4	210.9
Mergers, acquisitions and divestments	0.6	0.6	3.3	4.1
Restructuring and major corporate projects	21.9	3.3	35.9	12.7
Underlying EBITDA	109.3	89.3	289.6	227.5
Underlying non-core EBITDA	3.4	4.0	8.5	10.4
Underlying core EBITDA	105.8	85.3	281.1	217.1

Adjusted Net Income

The adjusted net income reached € 118.7 million in the reporting period, up from € 65.5 million in the prior year. This corresponds to an adjusted net income margin of 9.7% compared to 5.6% in 2024. The increase in adjusted net income is primarily driven by improved operating results and a higher underlying EBITDA. Depreciation and amortization without impairments increased in the normal course of business. The interest result decreased by € 7.4 million compared to 2024 due to overall lower bank interest rates. Income taxes increased by € 9.7 million, driven by higher profitability in the current period.

ADJUSTED NET INCOME AND RECONCILIATION TO THE UNDERLYING EBITDA

	Q3		9M	
million €	2025	2024	2025	2024
Underlying EBITDA	109.3	89.3	289.6	227.5
D&A (excl. impairments)	-34.1	-32.0	-101.3	-94.7
Interest result	-13.0	-15.7	-40.1	-47.5
Income taxes	-12.2	-7.7	-29.6	-19.9
Ordinary deduction items	-59.3	-55.5	-170.9	-162.1
Adjusted net income	50.0	33.9	118.7	65.5
MPP and IPO costs	-17.3	-0.5	-24.5	-6.8
Other extraordinary items	-5.1	-3.2	-14.6	-9.8
Extraordinary items	-22.6	-3.7	-39.2	-16.6
Impairments	-1.0	-2.0	-31.2	-17.6
Other financial result	1.7	-2.4	8.3	-9.6
Deferred tax expense	-1.7	0.4	-2.2	4.1
Other deduction items	-1.1	-4.1	-25.2	-23.1
Profit (loss) for the period	26.4	26.0	54.3	25.7

The increase in extraordinary items includes IPO costs and the associated revaluation of the MPP. The additional € 4.8 million in extraordinary expenses and € 13.7 million in impairment losses primarily relate to the intended divestment of the human mobility business. The other financial result was positively impacted by the re-valuation of foreign exchange derivatives. The profit (loss) for the period increased by € 28.6 million to € 54.3 million.

Free Cash Flow

Free cash flow amounted to € 172.8 million in the reporting period, which corresponds to an increase of 55.0% compared to the prior-year period. This development is mainly attributable to a significant improvement in cash flow from operating activities, which is driven by revenue growth and increased profitability.

Subsequent Events

Since October 9, 2025, Ottobock SE & Co. KGaA is listed in the Prime Standard of the Frankfurt Stock Exchange. Proceeds from the sale of new shares through a capital increase total approximately € 100.0 million.

On October 25, 2025, Ottobock has expanded its investment in ONWARD Medical N.V., a European medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities. ONWARD Medical successfully raised gross proceeds of € 50.9 million by way of an accelerated bookbuild offering through a private placement with existing and new institutional investors. Ottobock acted as cornerstone investor in this transaction by investing € 10.0 million and maintains its role as largest shareholder.

Guidance 2025

Based on the positive business performance in the first nine months of the current year, Ottobock specifies its full-year guidance for the Group. The core business is expected to grow in the upper half of 10.0% – 13.0% (including M&A activities). Organic core revenue growth is expected in the upper half to range between 9.0% – 12.0%. Underlying Core EBITDA margin is confirmed between 25.0% – 26.0%.

Consolidated Financial Statements

Consolidated statement of profit or loss

million €	Q3		9M	
	2025	2024	2025	2024
Revenue	417.2	401.7	1,217.8	1,164.5
Cost of sales	-195.5	-191.5	-572.4	-579.7
Gross profit	221.7	210.2	645.4	584.8
Other income	9.3	1.7	20.7	18.7
Selling and distribution expenses	-87.7	-84.3	-256.6	-251.8
Research and development expenses	-17.0	-18.5	-54.4	-52.7
Administrative expenses	-66.8	-34.8	-183.9	-157.4
Other expenses	-7.7	-22.8	-53.3	-43.1
Operating profit	51.7	51.6	117.9	98.7
Interest income	0.6	0.7	2.8	2.3
Interest expenses	-13.6	-16.4	-42.9	-49.8
Other financial result	1.5	-2.4	8.1	-9.6
Financial result	-11.4	-18.1	-31.8	-57.1
Profit before tax	40.3	33.5	86.1	41.6
Income tax expense	-13.9	-7.5	-31.8	-15.9
Profit (loss) for the period	26.4	26.0	54.3	25.7
Of which attributable to:				
- Shareholders of Ottobock SE & Co. KGaA	26.5	25.2	55.9	26.9
- Non-controlling interests	-0.1	0.9	-1.6	-1.2
Earnings per share				
Basic/diluted earnings per share*	€ 0.41	€ 0.39	€ 0.87	€ 0.42

* The number of ordinary shares outstanding increased as a result of the capital increases in August and October 2025. The calculation of basic earnings per share for all periods presented is based on the new number of shares.

Consolidated statement of other comprehensive income

million €	Q3		9M	
	2025	2024	2025	2024
Profit (loss) for the period	26.4	26.0	54.3	25.7
Cash flow hedge reserve	0.8	-3.4	2.9	-0.5
Exchange differences on translation of foreign operations	-4.9	-23.9	-29.6	-13.1
Items that may be reclassified to profit or loss (net of tax)	-4.1	-27.3	-26.7	-13.6
Remeasurement gain on defined benefit plans	0.0	-0.0	0.8	0.2
Net loss on equity instruments designated at fair value through OCI	3.2	0.0	-0.3	0.0
Items not reclassified to profit or loss (net of tax)	3.2	-0.0	0.5	0.2
Other comprehensive loss for the period (net of tax)	-0.8	-27.3	-26.2	-13.4
Total comprehensive income for the period, net of tax	25.5	-1.3	28.1	12.3
Of which attributable to:				
- Shareholders of Ottobock SE & Co. KGaA	25.7	-1.9	29.6	13.4
- Non-controlling interests	-0.2	0.7	-1.5	-1.1

Consolidated statement of financial position

Assets

million €	30 September 2025	31 December 2024
Property, plant and equipment	235.0	243.2
Intangible assets	844.3	851.3
Right-of-use assets	199.3	204.5
Equity-accounted investees	9.2	2.7
Derivatives	4.7	6.3
Other non-current financial assets	34.2	33.7
Other non-current assets	3.4	2.2
Deferred tax assets	76.4	80.1
Non-current assets	1,406.4	1,424.0
Inventories	231.1	221.0
Trade and other receivables	212.9	223.6
Derivatives	8.6	1.9
Other current financial assets	6.0	5.0
Cash and cash equivalents	99.4	76.7
Other current assets	55.3	46.7
Income tax assets	14.0	21.6
Current assets	627.3	596.6
Assets held for sale	19.9	-
Total assets	2,053.6	2,020.5

Consolidated statement of financial position (continued)

Liabilities

million €	30 September 2025	31 December 2024
Subscribed capital	62.5	5.5
Share premium	51.7	108.7
Retained earnings	189.3	148.8
Other components of equity	-49.4	-23.0
Equity attributable to shareholders of the parent	254.2	239.9
Non-controlling interests	6.8	9.6
Total equity	261.0	249.5
Interest-bearing loans and borrowings	829.5	966.3
Lease liabilities	164.8	170.4
Derivatives	4.2	5.6
Other non-current financial liabilities	10.3	7.2
Provisions	5.9	6.2
Contract liabilities	40.6	35.1
Employee benefits	23.8	24.5
Other non-current liabilities	3.8	11.7
Deferred tax liabilities	63.9	57.1
Non-current liabilities	1,146.7	1,284.2

million €	30 September 2025	31 December 2024
Interest-bearing loans and borrowings	145.8	25.5
Lease liabilities	41.2	42.6
Trade and other payables	84.4	101.2
Contract liabilities	34.1	31.4
Other current financial liabilities	20.1	31.9
Payables from reverse factoring	68.9	61.8
Derivatives	2.2	6.4
Income tax payable	31.4	36.4
Provisions	28.0	20.6
Employee benefits	123.3	90.8
Other current liabilities	52.6	38.2
Current liabilities	631.9	486.9
Liabilities directly associated with the assets held for sale	13.9	-
Total liabilities	1,792.6	1,771.0
Total equity and liabilities	2,053.6	2,020.5

Consolidated statement of cash flows

million €	Q3		9M	
	2025	2024	2025	2024
Profit before tax	40.3	33.5	86.1	41.6
Financial result	11.4	18.1	31.8	57.1
Depreciation, amortization and impairment	35.1	34.0	132.5	112.2
Results from disposals of non-current assets	-0.1	0.2	-0.6	0.1
Changes from long-term incentive plan	12.1	-	17.5	7.3
Other non-cash expenses/income	-0.1	-3.3	-5.0	-2.9
Change in inventories	-2.4	-9.6	-25.4	-35.1
Change in trade and other receivables	10.9	17.8	15.5	11.4
Change in other assets	-0.1	4.2	-8.2	-3.5
Change in provisions	3.9	4.6	4.9	-8.6
Change in trade and other payables	4.1	-1.9	-15.6	4.4
Change in other liabilities	22.5	2.2	42.6	0.3
Income tax paid	-29.6	-2.9	-33.3	-13.6
Net cash provided by operating activities	108.0	96.9	242.8	170.7
Purchase of tangible and intangible assets	-28.9	-24.2	-76.1	-65.7
Proceeds from sales of fixed assets	0.6	2.7	6.1	6.5
Free cash flow	79.6	75.4	172.8	111.5
Acquisition of subsidiaries (net of cash acquired)	-12.2	-33.5	-29.6	-49.6
Payment of earn-outs and deferred purchase prices	-8.0	-	-10.5	-
Acquisition of other investments	-	-	-6.6	-
Payments for other financial assets	-	10.1	-1.6	10.1
Proceeds from disposal of subsidiaries (net of cash disposed)	-	-0.1	-	0.3
Dividends received	0.3	-	0.3	-
Cash flows from investing activities	-48.3	-45.0	-118.1	-98.5

Consolidated statement of cash flows (continued)

million €	Q3		9M	
	2025	2024	2025	2024
Proceeds from loans and borrowings	-24.6	-672.2	-17.5	82.8
Repayment of loans and borrowings	-	665.0	-	-
Repayment of lease liabilities	-10.6	-10.7	-32.2	-32.4
Change in other financial liabilities	-	6.1	-	-1.8
Payment of dividends	-0.1	-	-15.1	-15.9
Payment for purchase of non-controlling interests	-0.9	-	-0.9	-5.5
Interest paid	-12.8	-18.6	-41.0	-51.0
Transaction costs for loans and borrowings	-	11.2	-	-
Change in other financing activities	2.0	-13.2	7.1	-15.6
Cash flows from financing activities	-47.0	-32.4	-99.5	-39.4
Change in cash and cash equivalents	12.7	19.5	25.3	32.8
Cash and cash equivalents at the beginning of the period	87.8	76.6	76.7	65.3
Effects of exchange rate changes	-1.2	-2.8	-2.0	-1.7
Reclassifications relating to assets held for sale	0.1	3.1	-0.5	-
Cash and cash equivalents at the end of the period	99.4	96.4	99.4	96.4

Further Information

Financial calendar

19 March 2026

Annual Report 2025, Analyst Conference Call

6 May 2026

Quarterly Statement January – March 2026

19 May 2026

Annual General Meeting

13 August 2026

Half-year Financial Report January – June 2026

12 November 2026

Quarterly Statement January – September 2026

Contact

Investor contact:

Julia Hartmann

Vice President Investor Relations

Mobile +49 151 55684807

E-Mail: JULIA.HARTMANN@OTTOBOCK.DE

Media contact:

Merle Florstedt

Head of Corporate Communications

Mobile +49 151 441 616 25

E-Mail: MERLE.FLORSTEDT@OTTOBOCK.DE

Layout and design concept

Kirchhoff Consult GmbH, Hamburg

WWW.KIRCHHOFF.DE

Forward-looking statements

This financial report includes statements concerning the future performance of Ottobock. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Ottobock undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this financial report.

Other information

The present document is a quarterly statement pursuant to Section 53 of the Exchange Rules for the Frankfurter Wertpapierbörse (BörsO FWB). It was drawn up according to International Financial Reporting Standards (IFRS) as applicable in the EU, but does not constitute an interim financial report as defined by IAS 34 "Interim Financial Reporting" or a financial statement as defined by IAS 1 "Presentation of Financial Statements". The accounting policies essentially correspond to those applied in the consolidated financial statement as at 31 December 2024.

In many places in the report, we have opted to forego the use of separate masculine and feminine forms in the interest of legibility. The masculine form is substituted for all genders.

The key figures in the report are rounded in accordance with standard commercial practice. In individual cases, rounding may result in values in this report not adding up precisely to the amount stated, with corresponding percentages not tallying.

This Interim Statement was published on 13 November 2025. It is available in German and English. In the event of any discrepancies between the two versions, the German version shall take precedence.

Published by

Ottobock SE & Co. KGaA
Max-Näder-Str. 15
37115 Duderstadt
Germany

#WeEmpowerPeople
www.ottobock.com